HOME >> BIOLOGY >> NEWS
Scientists seek genetic clues to emphysema and chronic bronchitis

DENVER - We have all heard people downplay the dangers of smoking by describing the friend or relative who has smoked three packs a day for 25 years and is still healthy as an ox. It's true that some smokers are lucky enough to escape serious lung disease. But it is also true that approximately one quarter of all smokers eventually develop emphysema and/or chronic bronchitis, collectively known as chronic pulmonary obstructive disease (COPD). Researchers at National Jewish Medical and Research Center are trying to learn what separates the smokers who stay healthy from the ones who develop COPD. They believe the answers lie in the smokers' genes.

"We believe a person's genes cause them to produce a protein that protects their lungs against smoke-induced damage, or one that makes them more susceptible to damage by smoke," said National Jewish pulmonologist Barry Make, M.D. "We are looking for genetic differences between people who appear susceptible to COPD and those who are not."

Dr. Make and his colleagues at National Jewish are joining researchers at nine other medical centers around the world in the largest study ever aimed at understanding the genetics of COPD. Discovery of genes associated with COPD could lead to better understanding of the disease, potentially new treatments and better warnings for susceptible people. The National Jewish research team is currently enrolling patients in the study, which is funded by GlaxoSmithKline.

The National Jewish research team is hoping to enroll as many as 600 families in its COPD genetics study. The researchers are looking for people between the ages of 45 and 65 who have been diagnosed with COPD and have either one living brother or sister who has also been diagnosed with COPD, or two siblings who smoke or have smoked in the past. The original COPD patient and his or her brother and/or sisters will all become part of the study.

Study participants will be asked to fill out a family questionnaire, gi
'"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
3-Apr-2001


Page: 1 2

Related biology news :

1. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
2. Scientists sequence genome of kind of organism central to biospheres carbon cycle
3. Scientists find nanowires capable of detecting individual viruses
4. Scientists discover potential new way to control drug-resistant bacteria
5. Scientists explore genome of methane-breathing microbe
6. Scientists decipher genetic code of biothreat pathogen
7. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins
8. Scientists discover proteins involved in spread of HIV-1 infection
9. Scientists fear new Ebola outbreak may explain sudden gorilla disappearance
10. Scientists reinvent DNA as template to produce organic molecules
11. Scientists visualise cellular handmaiden that restores shape to proteins

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Scientists seek genetic clues emphysema and chronic bronchitis

(Date:5/21/2013)... the nation,s land and water resources could likely support ... 25 billion gallons of algae-based fuel a year in ... , The findings come from an in-depth look at ... significant amounts of algae in large, specially built shallow ... issue of Environmental Science and Technology , published ...
(Date:5/21/2013)... a class of pharmaceuticals can both prevent and treat ... as "TSPO ligands," are currently used for certain types ... TSPO ligand in young adult mice when pathology was ... pathology was quite severe," said lead researcher Christian Pike ... reduced measures of pathology and improved behavior at both ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: